CD274 and cancer: We found that atezolizumab neutralized PD-L1 and activate immune responses, while acting synergistically with chondroitin sulfate (CS) on the outmost layer of the nanoparticles to target PD-L1 and CD44 for combined autophagy modulation and cancer immunotherapy.